M
Mersana Therapeutics
Platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives
About Mersana Therapeutics
Mersana Therapeutics is a biopharmaceutical company focused on discovering and developing innovative antibody-drug conjugates (ADCs) to treat cancer. The company leverages its proprietary technology platforms, Dolasynthen and Immunosynthen, to create a robust pipeline of ADCs designed to target and destroy cancer cells while sparing healthy tissue. Mersana operates in the oncology market, serving patients and healthcare providers who seek advanced treatment options for various types of cancer. The company's business model involves research and development, clinical trials, and partnerships with other pharmaceutical companies to bring its ADCs to market. Revenue is generated through public offerings, partnerships, and potential future sales of approved therapies. Mersana's multiprong strategy includes both cytotoxic and immunostimulatory ADCs, aiming to provide comprehensive solutions for cancer treatment.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2005
- Headquarters
- Cambridge, United States
- Listing
- IPO 2017
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Series B and later8 investors entered at this stage
F-Prime
Wellington Management
Cormorant Asset Management- HGHarris & Harris Group
- RPRho Capital Partners
- PIProQuest Investments
- RVRock Spring Ventures
- APArrowMark Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mersana Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mersana Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.



